GLP-1 is often used as a shorthand in discussions of diabetes and weight-management medicines. Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors, so its fuller description is a dual GIP/GLP-1 receptor agonist.
These category names help organise the subject, while an interaction search depends on the individual product. Use this hub to connect a familiar brand with its ingredient and formulation before exploring a record about a named medicine combination.
Connect the brand to the ingredient
Wegovy, Ozempic and Rybelsus are brands associated with semaglutide. Mounjaro and Zepbound contain tirzepatide. Recording both the brand and ingredient gives a pharmacist a clearer starting point than describing a product only as a GLP-1 medicine.
Also copy the form shown on the packaging. Semaglutide products include tablets and injections. Product-specific instructions and approved uses can differ, so ingredient recognition is the beginning of identification rather than evidence that products can be substituted.
Keep the record tied to its stated scope
Read the ingredient names and any formulation details before the interaction explanation. When an entry discusses another diabetes medicine, keep that exact combination in view rather than extending the statement to all glucose-lowering treatments or every medicine in this topic.
Product information may also discuss stomach emptying and other medicines taken by mouth. Ask whether the explanation applies to the named product and oral medicine being reviewed; a general category heading does not settle the relevance of a particular combination.
Bring the complete treatment context
Useful questions include: Is this record for my exact ingredient and formulation? Which other medicines need to be included in the review? Does anything in this explanation need discussion with the team overseeing my diabetes or weight-management treatment?
Include prescription medicines, nonprescription products and supplements in that conversation, together with recent changes. The product leaflet is a useful companion to an interaction record, and a pharmacist can help reconcile a brand name with the medicine described in it.
English medicine records
Open a medicine record to check its identity, sources and available information. Products, formulations and licensed uses can differ by country.
- Ozempic (semaglutide) Injection: Uses, Safety and InteractionsActive ingredient: Semaglutide
- Wegovy 0.25 mg pre-filled pen — Medicine information in EnglishActive ingredient: Semaglutide
- Rybelsus 7 mg (oral semaglutide): Uses, Formulations and SafetyActive ingredient: Semaglutide
- Mounjaro (tirzepatide): Uses, Pen Formulations and SafetyActive ingredient: Tirzepatide
- Saxenda (liraglutide): Weight Management, Safety and InteractionsActive ingredient: Liraglutide
- Trulicity 1.5 mg prefilled pen — Medicine information in EnglishActive ingredient: Dulaglutide
- Victoza 6 mg/mL prefilled pen — Medicine information in EnglishActive ingredient: Liraglutide
Documented interactions in English
Each link opens an existing, source-validated pair record. A missing record does not mean that there is no interaction.
- Coumadin 5 mg and Mounjaro 2.5 mg/0.5 ml Kalem — Interaction information
- Coumadin 5 mg and Victoza 6 mg/mL prefilled pen — Interaction information
- Diamicron MR 60 mg and Trulicity 1.5 mg prefilled pen — Interaction information
- Diamicron MR 60 mg and Victoza 6 mg/mL prefilled pen — Interaction information
- Saxenda 6 mg/ml Kalem and Trulicity 1.5 mg prefilled pen — Interaction information
- Saxenda 6 mg/ml Kalem and Victoza 6 mg/mL prefilled pen — Interaction information
Sources and scope
Sources checked: . Linked records carry their own sources and scope. Source checking is separate from review by a qualified clinician.